Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease (Q45298602)

11 December 2017

Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease (English)

1 reference

11 December 2017

0 references

8

1 reference

11 December 2017

Han-Yun Hsiao

1

1 reference

11 December 2017

Feng-Lan Chiu

2

1 reference

11 December 2017

Chiung-Mei Chen

3

1 reference

11 December 2017

Yih-Ru Wu

4

1 reference

11 December 2017

Hui-Mei Chen

5

1 reference

11 December 2017

Yu-Chen Chen

6

1 reference

11 December 2017

Hung-Chih Kuo

7

1 reference

11 December 2017

3 April 2014

1 reference

11 December 2017

Human Molecular Genetics

1 reference

11 December 2017

23

1 reference

11 December 2017

16

1 reference

11 December 2017

4328-4344

1 reference

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

11 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Local neuroinflammation and the progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Microglial activation in presymptomatic Huntington's disease gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Minocycline is protective in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Minocycline and doxycycline are not beneficial in a model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

TNF receptor subtype signalling: differences and cellular consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Signalling pathways of the TNF superfamily: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

The receptor for tumor necrosis factor on murine astrocytes: characterization, intracellular degradation, and regulation by cytokines and Theiler's murine encephalomyelitis virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Tumor necrosis factor blockade and the risk of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Infectious complications of tumor necrosis factor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

A sensitive and selective assay of neuronal degeneration in cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Effects of neuroinflammation on glia-glia gap junctional intercellular communication: a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Microglia and neuroinflammation: a pathological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Huntington disease models and human neuropathology: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

The role of IκB kinase complex in the neurobiology of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

6-Hydroxydopamine-induced alterations in blood-brain barrier permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Huntington's Disease: An Immune Perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Lack of minocycline efficiency in genetic models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pat

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Quantitative Limulus lysate assay for endotoxin and the effect of plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Effects of muscle fatigue on gait characteristics under single and dual-task conditions in young and older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDU151

21 January 2018

Identifiers

DOI

10.1093/HMG/DDU151

1 reference

11 December 2017

1 reference